Overview
5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme that plays a critical role in cellular energy metabolism. NNMT catalyzes the methylation of nicotinamide using S-adenosyl-L-methionine (SAM) as a methyl donor, effectively creating a metabolic 'sink' that depletes both NAD+ precursors and the universal methyl donor SAM. By inhibiting this enzyme, 5-Amino-1MQ may restore metabolic flux through more productive pathways.
Research interest in NNMT inhibition surged following the 2014 discovery that NNMT expression is significantly upregulated in white adipose tissue of obese individuals and in diet-induced obese (DIO) animal models. Studies at the University of Texas demonstrated that NNMT knockdown in mice increased energy expenditure by up to 30% and significantly reduced body weight without affecting food intake, positioning NNMT as a compelling therapeutic target.
Unlike many weight-loss peptides that act centrally on appetite pathways, 5-Amino-1MQ works at the cellular metabolic level, making it an orthogonal approach that could theoretically be combined with GLP-1 agonists or other appetite-modulating agents. The compound's small molecular weight (159.21 g/mol) also supports oral bioavailability, a significant advantage over injectable peptides.
While preclinical data is promising, 5-Amino-1MQ has not entered formal clinical trials and is not approved for human use. This guide examines the available research evidence, proposed mechanisms, and considerations for this novel metabolic modulator.
Quick facts
- Mechanism
- NNMT enzyme inhibitor restoring NAD+ and SAM availability
- Primary use
- Metabolic Enhancement & Fat Reduction
- Evidence
- moderate
- FDA
- Not approved
- Route
- Oral or subcutaneous injection
- Typical results
- Preclinical models show significant reductions in body fat and improved metabolic markers within 2–6 weeks
Chemical information
5-Amino-1MQ (C₁₀H₁₁N₂) is a metabolic compound with a molecular weight of 159.21 g/mol. Its structural characteristics underpin its biological activity in metabolic regulation and energy homeostasis.
How 5-Amino-1MQ works
5-Amino-1MQ competitively inhibits nicotinamide N-methyltransferase (NNMT), preventing the enzyme from methylating nicotinamide into 1-methylnicotinamide (1-MNA). This inhibition has cascading metabolic effects: it preserves SAM for critical methylation reactions (DNA methylation, histone modification, neurotransmitter synthesis) and maintains nicotinamide availability for NAD+ biosynthesis through the salvage pathway. The net result is enhanced cellular energy production and epigenetic regulation.
In adipose tissue, NNMT overexpression creates a metabolic bottleneck where excess nicotinamide is shunted toward 1-MNA production instead of being recycled into NAD+. This depletes the NAD+ pool essential for mitochondrial oxidative phosphorylation and sirtuin-dependent metabolic regulation. By blocking NNMT, 5-Amino-1MQ restores NAD+ levels, reactivating SIRT1-mediated lipolysis and mitochondrial biogenesis. Studies show that NNMT inhibition increases intracellular NAD+ by approximately 2-fold in adipocytes.
The SAM-preserving effect of NNMT inhibition also influences polyamine biosynthesis and histone methylation patterns. In muscle tissue, this leads to increased expression of genes involved in oxidative metabolism and energy expenditure. The compound has been shown to increase the expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a master regulator of mitochondrial biogenesis.
Additionally, NNMT inhibition reduces the expression of adipogenic transcription factors including PPARγ and C/EBPα, shifting mesenchymal stem cell differentiation away from adipogenesis and toward osteogenesis. This dual effect—increased fat burning combined with reduced new fat cell formation—may explain the robust anti-obesity effects seen in preclinical models.
- NNMT inhibition: Blocks the methylation of nicotinamide, preserving SAM and NAD+ precursors for productive metabolic pathways
- NAD+ restoration: Increases intracellular NAD+ levels, reactivating sirtuin-dependent lipolysis and mitochondrial function
- SAM conservation: Preserves S-adenosylmethionine for DNA methylation, histone modification, and polyamine synthesis
- Anti-adipogenic: Reduces PPARγ and C/EBPα expression, inhibiting new fat cell differentiation
- Energy expenditure: Upregulates PGC-1α and uncoupling proteins, increasing basal metabolic rate
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Molecular Weight | 159.21 g/mol | Small molecule enabling oral bioavailability unlike larger peptides |
| Half-life | ~4–6 hours (estimated) | Supports twice-daily oral dosing regimen |
| Bioavailability | Moderate oral bioavailability | Can be administered orally, avoiding injection requirements |
| Target | NNMT enzyme (IC50 ~1.5 μM) | Selective competitive inhibition of nicotinamide methylation |
Dosing & administration
5-Amino-1MQ dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for 5-Amino-1MQ is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Significant reduction of diet-induced obesity in preclinical models without affecting food intake
- • Enhanced cellular NAD+ levels supporting mitochondrial function and sirtuin activation
- • Improved insulin sensitivity and glucose tolerance in obese animal models
- • Reduced adipocyte size and white adipose tissue mass
- • Potential synergy with other metabolic interventions due to unique mechanism of action
- • Oral bioavailability advantage over injectable peptide therapies
Serious / potential risks
- • Limited human safety data available
- • Theoretical risk of SAM pathway disruption with excessive NNMT inhibition
- • Potential interactions with methylation-dependent medications
- • Unknown long-term effects on epigenetic regulation
- • May affect nicotinamide-dependent pathways beyond intended targets
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| NAD+ precursors (NMN, NR) | Potentially synergistic | May enhance NAD+ restoration; combination is theoretically beneficial but unstudied in humans |
| Metformin | Additive metabolic effects | Both activate AMPK pathways; monitor for hypoglycemia |
| SAM supplements | Potentially reduced need | NNMT inhibition preserves endogenous SAM; supplementation may be unnecessary |
| Methylation-dependent drugs | Altered methylation capacity | Monitor methylation-sensitive medications as SAM availability may change |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
5-Amino-1MQ is a metabolic compound with research interest in weight loss, metabolic health, fat metabolism. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying metabolic regulation and energy homeostasis
- • Individuals interested in weight loss under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Kraus D, Yang Q, Kong D, et al.. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature (2014). doi: 10.1038/nature13198 PMID: 24814345
- [2] Neelakantan H, Wang HY, Lauderdale V, et al.. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol (2018). doi: 10.1016/j.bcp.2017.11.007 PMID: 29155147
- [3] Hong S, Moreno-Navarrete JM, Wei X, et al.. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med (2015). doi: 10.1038/nm.3882 PMID: 26076035
- [4] Brachs S, Winber S, Gluber S, et al.. Inhibitors of nicotinamide N-methyltransferase designed to mimic the methylation reaction. Angew Chem Int Ed (2019). doi: 10.1002/anie.201814092 PMID: 30680868